Welcome to our dedicated page for Liquidia Corporation news (Ticker: LQDA), a resource for investors and traders seeking the latest updates and insights on Liquidia Corporation stock.
Liquidia Corporation (LQDA) is a biopharmaceutical innovator leveraging its proprietary PRINT® Technology to develop precision therapies for pulmonary hypertension and rare cardiopulmonary conditions. This page aggregates official company announcements, providing stakeholders with timely updates on clinical advancements, regulatory milestones, and strategic initiatives.
Investors and researchers will find curated press releases detailing progress in Liquidia’s pipeline, including YUTREPIA™ inhalation powder development, FDA communications, and technology licensing agreements. Content spans clinical trial results, manufacturing updates, and partnership announcements with global pharmaceutical entities.
Key categories include treatment efficacy studies, regulatory filings, intellectual property developments, and operational expansions. All materials adhere to factual reporting standards, ensuring reliable insights into the company’s scientific and business trajectory.
Bookmark this page for streamlined access to Liquidia’s latest verified updates. Combine regular visits with professional financial counsel to inform your investment strategy.
Liquidia (NASDAQ: LQDA) announced the FDA's acceptance of its New Drug Application (NDA) resubmission for YUTREPIA™ (treprostinil) inhalation powder. The treatment targets pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
The FDA classified the resubmission as a complete, Class 1 response to the previous action letter from August 16, 2024, which had granted tentative approval for both indications. The agency has set a Prescription Drug User Fee Act (PDUFA) goal date of May 24, 2025.
Liquidia (NASDAQ: LQDA) has announced three poster presentations at the upcoming American Thoracic Society (ATS) 2025 International Conference in San Francisco, scheduled for May 18-21, 2025.
Two posters will present new data from the ASCENT study of LIQ861 (YUTREPIA™) in PH-ILD patients, focusing on safety, tolerability, and exploratory changes in 6-minute walk distance, quality of life, and cardiac effort. The third poster features a case study from the INSPIRE study, examining long-term safety and tolerability in a PAH patient transitioning from parenteral treprostinil.
The presentations are scheduled for Tuesday, May 20, 2025, from 11:30 a.m. to 1:15 p.m. PT, with Dr. Rajan Saggar, Dr. Daniel Lachant, and Dr. Rodolfo Estrada as presenting authors. All posters will be available on Liquidia's website after the presentations.
Liquidia (NASDAQ: LQDA) reported its full year 2024 financial results, highlighting key developments and financial performance. The company is awaiting final FDA approval for YUTREPIA™ after regulatory exclusivity expires on May 23, 2025, following its tentative approval for PAH and PH-ILD treatment in August 2024.
Financial highlights include:
- Cash position of $176.5 million as of December 31, 2024
- Revenue decreased to $14.0 million from $17.5 million in 2023
- Net loss widened to $130.4 million ($1.66 per share) from $78.5 million in 2023
The company strengthened its financial position through an amended agreement with HealthCare Royalty Partners, providing access to up to $100 million in additional financing. The ASCENT study evaluating YUTREPIA in PH-ILD patients is nearing completion, while development of L606, a twice-daily liposomal treprostinil formulation, continues to progress.
Liquidia (NASDAQ: LQDA) has amended its agreement with HealthCare Royalty (HCRx) to secure up to $100 million in additional financing through three tranches:
- $25 million available at closing
- $50 million upon first commercial sale of YUTREPIA™ after FDA approval for PAH and PH-ILD treatment
- $25 million upon reaching $100 million in YUTREPIA sales by June 30, 2026
The funds will support YUTREPIA's commercial development, clinical trials including pediatric studies, L606 development, and general corporate purposes. The agreement includes fixed payment schedules until 2032, with payments capped at 175% of advanced amounts, plus potential true-up payments based on minimum return rates of 16%, 13%, and 12% for the three tranches.
Liquidia (NASDAQ: LQDA), a biopharmaceutical company focused on rare cardiopulmonary disease therapies, has scheduled the release of its full year 2024 financial results for March 19, 2025. The company will conduct a live webcast at 8:30 a.m. Eastern Time to present the financial results and provide a corporate update. Investors can access the webcast through Liquidia's website, where it will remain archived for one year.
Liquidia (NASDAQ: LQDA) has announced that its CEO, Dr. Roger Jeffs, will present at the 43rd Annual J.P. Morgan Healthcare Conference. The presentation is scheduled for Wednesday, January 15, 2025, at 9:45 a.m. Pacific Time (12:45 p.m. Eastern Time) at the Westin St. Francis in San Francisco, California.
The event will feature a live, audio-only webcast accessible via the “Investors” page on Liquidia’s website at https://liquidia.com/investors/events-and-presentations. For those unable to attend live, a replay and transcript of the webcast will be archived on the company's website for at least 30 days.
Liquidia (NASDAQ: LQDA) reported Q3 2024 financial results, highlighting key developments including FDA tentative approval for YUTREPIA™ for PAH and PH-ILD treatments. Revenue increased to $4.4M from $3.7M year-over-year. The company strengthened its balance sheet by raising approximately $100M through equity offering and financing agreement. Net loss widened to $23.2M ($0.30 per share) compared to $15.8M ($0.24 per share) in Q3 2023. Cash position improved to $204.4M as of September 30, 2024. Launch of YUTREPIA is currently gated until May 23, 2025, due to TYVASO DPI's exclusivity period.
Liquidia (NASDAQ: LQDA), a biopharmaceutical company focused on rare cardiopulmonary disease treatments, has announced its upcoming presentation at the Stifel 2024 Healthcare Conference in New York City. The presentation is scheduled for Tuesday, November 19, 2024, from 3:00 to 3:30 p.m. ET.
Investors and interested parties can access the live webcast through Liquidia's website investor section. A recorded version will remain available on the company's website for at least 30 days after the event.
Liquidia (NASDAQ: LQDA), a biopharmaceutical company focused on rare cardiopulmonary disease therapies, has rescheduled its third quarter 2024 financial results announcement to November 13, 2024. The date change accommodates SEC filing rules affected by the November 11 federal holiday. The company will host a webcast at 8:30 a.m. Eastern Time to discuss results and provide a corporate update. The webcast will be accessible on Liquidia's website and archived for one year.
Liquidia (NASDAQ: LQDA), a biopharmaceutical company focused on rare cardiopulmonary disease therapies, has scheduled its third quarter 2024 financial results announcement for November 11, 2024. The company will host a live webcast at 8:30 a.m. Eastern Time to discuss financial performance and provide a corporate update. The webcast will be accessible through Liquidia's website and will remain archived for one year.
FAQ
What is the current stock price of Liquidia Corporation (LQDA)?
What is the market cap of Liquidia Corporation (LQDA)?
